* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Patel, Devina
Idiopathic intracranial hypertension wikipedia , lookup
Vision therapy wikipedia , lookup
Optical coherence tomography wikipedia , lookup
Mitochondrial optic neuropathies wikipedia , lookup
Fundus photography wikipedia , lookup
Blast-related ocular trauma wikipedia , lookup
Photoreceptor cell wikipedia , lookup
Visual impairment due to intracranial pressure wikipedia , lookup
Retinitis pigmentosa wikipedia , lookup
A Case of Something More Than What Meets the Clinical Observer’s Eye – Devina Patel, OD ABSTRACT: 29yof h/o POHS, 20/20 OD/OS and h/o OS parafoveal scar, presents sudden VA loss to CF OS. Exam positive for APDOS, unchanged scar. IRCSLO, Autofluorescence and SDOCT identify new outer retinal pathologic process not evident on funduscopy. Multimodal imaging reveals new diagnosis. I. CASE HISTORY a. Patient Demographics: 29 year old female born and raised in Texas b. Chief Complaint: Sudden unilateral vision loss accompanied with pain at onset one month ago. Patient woke up with head pain graded as a 7/10 (dull, over left brow). Vision disturbance initially presented “as though everything was 3-D” per history. Patient covered each individually to discover that she was unable to see anything out of her left eye. Patient denied photopsias or other visual disturbances. c. Ocular History: Patient has history of Presumed Ocular Histoplasmosis diagnosed in 2005. At time of diagnosis patient also reports having had an intravitreal injection she believes was steroidal in nature. At a subsequent followup visit patient was noted to have an IOP of 46 in the same eye, consistent with a steroid response. Patient was treated with Alphagan bid for about two months. No recurrence or impact on visual outcome at that time. d. Medical History: Unremarkable e. Medications: Lipo-6 weight loss supplement II. PERTINENT FINDINGS a. Clinical: i. Best corrected visual acuity OD: 20/20 OS: CF @ 3 ft. with eccentric fixation (where OS was previously 20/20) ii. Refractive error: Moderate myopia – OD: -3.00 sph OS: -3.25 sph iii. FCF full OD & restricted OS 360 iv. Pupils: OS>OD; sluggish response OS; (+) 1+/2 APD OS v. EOM’s: FESA vi. Amsler grid: testing revealed no abnormalities in the right eye, whereas there was a complete scotoma OS sparing ~4 degrees infero-temporally. vii. Color Vision (Ishihara): OD: 10/10; OS: unable to see plates due to central scotoma viii. Anterior Segment: 1. Unremarkable: no endothelial keratic precipitates OU; no anterior chamber reaction OU ix. Intraocular Pressure by Goldmann Applanation Tonometry: 1. OD: 13 2. OS: 12 @ 9:25 AM x. Dilated Fundus Examination: 1. Vitreous: clear OD & OS; no vitritis OU 2. OD: distinct ONH margins; C/D: 0.60hx0.55v c temporal PPA; no pallor, no disc edema 3. OS: distinct ONH margins; C/D: 0.50x.50 c temporal PPA; no pallor, no disc edema b. c. d. e. 4. Posterior Pole: OD: very small punched out parafoveal hypopigmented lesions OS: parafoveal macular scar ~1/3 DD in size; no subretinal fluid; no hemorrhages; additional punched out lesion superior to macula – hyperpigmented with whitish ring; small circular hypopigmented circular lesion inferonasal to ONH 5. Periphery: OD: lattice degeneration inferiorly OS: lattice degeneration inferiorly and superotemporally Physical: Review of Systems: Within Normal Limits Laboratory Studies: i. Histoplasmosis antibody test: not performed Radiological Studies: i. Recent MRI performed for this problem: negative for multiple sclerosis plaques; positive for mild sinusitis Other: i. Humphrey Visual Field Testing (OSx2) 1. OD: clean, reliable, repeatable 2. OS: central scotoma, scattered disorganized defects with no repeatable pattern ii. Goldmann Visual Field Testing 1. No restrictions OD & OS iii. Confocal Scanning Laser Ophthalmoscope: 1. Infra red CSLO shows patchy irregular signal OS; Short wavelength (488nm) CSLO and short wavelength autofluorescence reveal irregular deep retinal reflectance pattern change compared to scans 1 year ago. iv. IVFA 1. No leakage indicative of CNVM OU v. High Resolution Spectral Domain OCT: 1. OD: Scan through small parafoveal punched out lesions revealed no significant extension or damage to fovea ; CMT: 189 2. OS: Scan through punched out macular histo spot revealed discontinuity of ISOS line at FAZ and throughout posterior pole, photoreceptor atrophy at fovea & throughout clinically defined macula, outer retinal disorganization as well as accumulation of material in outer neurosensory retina beneath histo spot that does not show autofluorescent properties; CMT: 197 vi. Standard Digital Fundus Photography: Photography performed 1 year apart shows no observable change in macular lesion OS. III. DIFFERENTIAL DIAGNOSES a. Primary: i. Punctate Inner Choroidopathy ii. POHS Reactivation b. Other: i. Subretinal Fibrosis & Uveitis Syndrome ii. Multifocal Choroiditis with Panuveitis iii. Acute Macular Neuroretinopathy iv. Retrobulbar Optic Neuritis IV. DIAGNOSES & DISCUSSION a. Elaboration on the condition: Ocular histoplasmosis presents as a triad of punched out chorioretinal histo spots, peripapillary atrophy and macular choroidal neovascular membranes predominantly in females 20-50 years of age. Disseminated lesions present initially, with macular involvement following many years later. In this case, a 29 year old myopic female is diagnosed with POHS and maintains a BCVA of 20/20 until 4 years after diagnosis. There is no clinically observable change in the macular lesion that has been stable since time of diagnosis. IVFA shows no sign of active CNVM. In the absence of vitritis or uveitis, a White Dot Syndromes such as Punctate Inner Chorioretinopathy should be considered. PIC is characterized by development of subretinal fibrosis formed by coalescence and evolution of acute lesions that greatly mimic histo spots. In this case, high resolution spectral domain OCT shows significant outer retinal disorganization and photoreceptor atrophy in a patchy distribution throughout the macular area. There is a generalized discontinuity of the IS/OS line in both eyes. OCT findings are supported by corresponding regional changes in CSLO imaging features to long and short wavelengths. Further diagnostic testing should include multifocal ERG. b. Expound on unique features: Initial diagnosis of POHS was made in 2005, at which time macular scar in the left eye was documented and patient was treated with intravitreal steroid injection. Best corrected visual acuity remained 20/20 OS up until 2008. When patient presented in 2009 with complain of sudden unilateral vision loss, no evidence of CNVM was noted and macular scar OS appeared to be unchanged and consistent with prior year’s photodocumentation. Fundus appearance remained unchanged to conventional examination but imaging with advanced diagnostic instrumentation modifies the original diagnosis. V. TREATMENT, MANAGEMENT a. Treatment and response to Tx: Pending definitive diagnosis– no treatment at present time due to lack of active CNVM. b. References to Literature: i. The Macular Photocoagulation Study: showed that argon or krypton laser Tx reduced vision loss in POHS patients with juxtafoveal or extrafoveal CNVM. There is no benefit of prophylactic treatment in absence of an active membrane. ii. A study by Rivers et al. retrospectively reviewed 208 patients with already diagnosed POHS. It focused on cases of 7 individuals, with existing POHS scars, who presented with new symptoms of decreased vision or metamorphopsia. IVFA performed on all aforementioned patients was not conclusive due to CNVM growing within the margins of a longstanding atrophic scar. iii. Watzke initially described the clinical entity of Punctate Inner Chorioretinopathy in 1984. The condition is characterized by blurred vision or central scotoma at initial presentation most commonly in young, moderately myopic females. Additional presenting symptoms may include flashes, floaters and photopsias. Although symptoms are typically unilateral, fundusopic examination more often than not reveals bilateral lesions that are described as multiple discrete, flat, yellow, round, punched-out spots at the level of the RPE and choroid. PIC is distinguished from other white dot syndromes by the absence of anterior and posterior segment inflammation. The most threatening aspect of PIC is the development of a choroidal neovascular membrane, which if present, significantly diminishes visual prognosis. It is estimated that 1740% of patients with PIC will develop CNVM. c. Bibliography: i. Alexander LJ. Primary Care of the Posterior Segment. 3rd Edition: 146154. McGraw Hill. 2002. ii. Amaro MH, Muccioli C, Abreu MT. “Ocular histoplasmosis-like syndrome: a report from a nonendemic area”. Arq Bras Oftalmol. 70(4):577-580. 2007. iii. Amin P, Cox TA. “Acute Macular Neuroretinopathy”. Archives of Ophthalmology. 116:112-113. 1998. iv. Foster CS, Vitale AT. Treatment, Diagnosis and Management of Uveitis. Edition 1, Saunders. 2002. v. Gerstenblith AT, Thorne JE, Sobrin L, et al. “Punctate Inner Chorioretinopathy: A Survery Analysis of 77 Persons”. Ophthalmology. 114(6): 1201-1204. 2007. vi. Hawkins BS, Alexander J, Schachat AP. Inflammatory Disease: Ocular Histoplasmosis. Section 6, Ch. 103: 1661-1673. vii. Jost BF, Olk RJ, Burgess DB. “Factors Related to Spontaneous Visual Recovery in the Ocular Histoplasmosis Syndrome”. Retina, The Journal of Retina and Vitreous. 7(1):1-8. 1987. viii. Kedhar SJ, Thorne JE, Wittenberg S, et al. “Multifocal Choroiditis with Panuveitis and Punctate Inner Chorioretinopathy: Comparison of Clinical Characteristics at Presentation”. Retina, The Journal of Retina and Vitreous. 27(9):1174-1179. 2007. ix. Matsumoto Y, Haen SP, Spaide RF. “Clinical Practice: The White Dot Syndromes”. Comprehensive Ophthalmology Update. 8(4): 179-200. 2007. x. Monson BK, Greenberg PB, Greenerg E, et al. “High-speed, ultra-highresolution optical coherence tomography of acute macular neuroretinopathy”. British Journal of Ophthalmology. 91:119-120. 2007. xi. Morgan CM, Schatz, H. “Recurrent Multifocal Choroiditis”. Ophthalmology. 93(9):1138-1147. 1986. xii. Peyman GA, Lad EM, Moshfeghi DM. “Intravitreal Injections of Therapeutic Agents”. Retina, The Journal of Retina and Vitreous Diseases. 29(7):875-912. xiii. Rivers MB, Pulido JS, Folk JC. “Ill-defined Choroidal Neovascularization within Ocular Histoplasmosis Scars”. Retina, The Journal of Retina and Vitreous. 12(2)90-95. 1992. xiv. Sieving PA, Fishman GA, Salzano T, et al. “Acute macular neuroretinopathy: early receptor potential change suggests photoreceptor pathology”. British Journal of Ophthalmology. 68:229-234. 1984. xv. Thorne JE, Wittenberg S, Kedhar SR, et al. “Optic Neuropathy Complicating Multifocal Choroiditis and Panuveitis”. American Journal of Ophthalmology. 143(4):721-723. 2007. xvi. Quillen DA, Davis JB, Gottlieb JL, et al. “Perspective: The White Dot Syndromes”. The American Journal of Ophthalmology. 137(3):538-549. Elsevier Inc. 2004. xvii. Watzke RC, Packer AJ, Folk JC, et. al. “Punctate Inner Chorioretinopathy”. American Journal of Ophthalmology. 98(5):572584. 1984. VI. CONCLUSION a. In conclusion, a 29 year old female with Presumed Ocular Histoplasmosis presents with a profound, acute onset, unilateral vision loss from 20/20 to counting fingers at 3 feet. There is no obvious sign of choroidal neovascular membrane in the area of longstanding parafoveal scar. In the absence of any funduscopic change, outer retinal pathology evidenced only with multimodal imaging demonstrates critical findings that modify original diagnosis. b. Clinical Pearls: i. White dot syndromes such as Multifocal Choroiditis and Punctate Inner Chorioretinopathy should be considered in unilateral cases of POHS, especially in absence of uveitis or vitritis. ii. Punched out lesions associated with POHS may increase in size and number after initial dissemination, possibly on a subclinical level. iii. Patients who present with atypical or inconsistent findings may benefit from additional imaging beyond IVFA, such as CSLO tomography and high resolution spectral domain OCT for key data to further elucidate clinical status.